Glioblastoma: all 1,951 studies

Page 11 of 20. Open to participants first (457), then studies with results posted, then the rest; newest registration first within each.

• Evaluate the Safety and Preliminary Efficacy of the Combination of NaviFUS System With Re-irradiation for rGBM PatientsCompletedNCT04988750Not applicable
• A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor CancerTerminatedNCT04982926Phase 1
• A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine GliomaActive, not recruitingNCT04978727Phase 1
• Impact of Bevacizumab on Symptom Burden and Neurological Deficits in Patients With Recurrent GlioblastomaCompletedNCT04974983
• Educating Brain Tumor Patients Using Patient-specific Actual-size Three-dimensional Printed ModelsStatus unknownNCT04970615
• RENEW: Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the Treatment of Newly Diagnosed Glioblastoma Patients.TerminatedNCT04963413Phase 1
• Newly Diagnosed GlioblastomaActive, not recruitingNCT04959500Phase 2
• Combined Treatment of Camrelizumab and Bevacizumab for Adult Patients with Recurrent Glioblastoma (GBM)TerminatedNCT04952571Phase 2
• The PCSK9i Inhibitor Evolocumab - a Surgical Trial of Pharamcodynamics and Kinetics EvaluationCompletedNCT04937413Early Phase 1
• Phase II Trial of Romiplostim for Thrombocytopenia Induced by Lomustine at First Progression of MGMT Promoter-meth GlioblastomaWithdrawnNCT04933942Phase 2
• 6 Months Adjuvant Temozolomide (TMZ) vs No Adjuvant TMZ in Newly Diagnosed MGMT Methylated Glioblastoma (GBM)WithdrawnNCT04926168
• Radiation/Temozolomide and Immunotherapy With Daratumumab to Improve Antitumor Efficacy in GlioblastomaActive, not recruitingNCT04922723Phase 1/2
• Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV)TerminatedNCT04915404Phase 1/2
• Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor MalignanciesActive, not recruitingNCT04913337Phase 1/2
• Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent GlioblastomaActive, not recruitingNCT04910022Phase 1/2
• Effect of Radiotherapy Concurrent of TTFields in Patients With GlioblastomaStatus unknownNCT04902586Not applicable
• Neoadjuvant PD-1 Antibody Alone or Combined With DC Vaccines for Recurrent GlioblastomaStatus unknownNCT04888611Phase 2
• AGuIX Nanoparticles With Radiotherapy Plus Concomitant Temozolomide in the Treatment of Newly Diagnosed GlioblastomaActive, not recruitingNCT04881032Phase 1/2
• MBM-02 (Tempol) for the Treatment of Glioblastoma Multiforme (GBM)Status unknownNCT04874506Phase 2
• Neuro-pharmacological Properties of Repurposed Ketoconazole in GlioblastomasTerminatedNCT04869449Early Phase 1
• Patient-derived Glioma Stem Cell OrganoidsActive, not recruitingNCT04868396
• Iodine-125 Brachytherapy Together With Chemotherapy in Patients With Newly Diagnosed GlioblastomaStatus unknownNCT04856852Not applicable
• ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent GlioblastomaWithdrawnNCT04854044Phase 1
• Specific Preoperative Dynamic Contrast-enhanced MRI Semi-quantitative Markers Can Correlate With Vascularity in Specific Areas of the Glioblastoma Tissue and Predict RecurrenceCompletedNCT04846257
• Sonodynamic Therapy with ExAblate System in Glioblastoma PatientsCompletedNCT04845919Phase 2
• Multi Peptide Vaccination with XS15 in Addition to Standard Postoperative Radiation Therapy and Temozolomide Chemotherapy in Newly Diagnosed GlioblastomaCompletedNCT04842513Phase 1
• Radiotherapy Planning Using Fluciclovine PET in Patients With Newly Diagnosed GlioblastomaStatus unknownNCT04840069Phase 2
• Role of Repeat Resection in Recurrent GlioblastomaWithdrawnNCT04838782Not applicable
• Neoadjuvant Temozolomide Combined With Simultaneous IMRT for Treatment of GlioblastomaStatus unknownNCT04829097Phase 3
• ASP8374 + Cemiplimab in Recurrent GliomaCompletedNCT04826393Phase 1
• Analysis of Cell Count, Viability, and Immunogenicity of Discarded Newly Diagnosed Glioblastoma Tissue or Solid Tumor TissuesCompletedNCT04822688
• Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or GliosarcomaCompletedNCT04817254Phase 2
• Glioblastoma Response Prediction to ApatinibCompletedNCT04814329
• Regorafenib in Patients With Relapsed Glioblastoma. IOV-GB-1-2020 REGOMA-OSSCompletedNCT04810182
• A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated GliomasActive, not recruitingNCT04808245Phase 1
• SurVaxM Expanded Access ProtocolNo longer availableNCT04802447
• Immunotherapy With Autologous Tumor Lysate-Loaded Dendritic Cells In Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT04801147Phase 1/2
• FET-PET Directed Simultaneous In-field Boost for Primary GBMCompletedNCT04790097Not applicable
• Study of Icapamespib (PU-AD) in Patients With Recurrent Malignant GliomaTerminatedNCT04782609Phase 1
• Multimodality MRI and Liquid Biopsy in GBMWithdrawnNCT04776980Early Phase 1
• Chloroquine for Glioblastoma.Status unknownNCT04772846Phase 1/2
• Recurrent GBM With Maximal Neurosurgical Removal and Treatment With IORTTerminatedNCT04763031Not applicable
• A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma MultiformeActive, not recruitingNCT04762069Phase 2
• Tadalafil to Overcome Immunosuppression During Chemoradiotherapy for IDH-wildtype Grade III-IV AstrocytomaCompletedNCT04757662Phase 1
• A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)Active, not recruitingNCT04752813Phase 2
• Analyzing Pulsed Reduced Dose Radiotherapy in Upfront GlioblastomaActive, not recruitingNCT04747145Phase 2
• Monocyte Antigen Carrier Cells for Newly Diagnosed GBMWithdrawnNCT04741984Phase 1
• Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRdCompletedNCT04740190Phase 2
• SonoClear Acoustic Coupling Fluid (ACF) Mimicking Brain TissueCompletedNCT04734444Not applicable
• Metabolic Therapy Program In Conjunction With Standard Treatment For GlioblastomaCompletedNCT04730869Not applicable
• UNIty-Based MR-Linac Guided AdapTive RadiothErapy for High GraDe Glioma: a Phase 2 TrialCompletedNCT04726397Not applicable
• Anlotinib Combined With STUPP for MGMT Nonmethylated GlioblastomaStatus unknownNCT04725214Phase 2
• Pilot Study of NKG2D CAR-T in Treating Patients With Recurrent GlioblastomaStatus unknownNCT04717999Not applicable
• TIGER PRO-Active - Daily Activity, Sleep and Neurocognitive Functioning StudyStatus unknownNCT04717739
• Systemic and Local Levels of Lidocaine During Surgery for the Removal of GlioblastomaCompletedNCT04716699Phase 1
• Niraparib Combined With Radiotherapy in rGBMStatus unknownNCT04715620Phase 2
• Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.TerminatedNCT04712721Early Phase 1
• A Pilot Study of Ketogenic Diet and Metformin in Glioblastoma: Feasibility and Metabolic ImagingActive, not recruitingNCT04691960Phase 2
• A Prospective, Open-label, Single-arm Clinical StudyStatus unknownNCT04689087Not applicable
• Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and BevacizumabTerminatedNCT04681677Phase 2
• Study of Niacin in GlioblastomaActive, not recruitingNCT04677049Phase 1/2
• Automatic Segmentation MRI Cerebral GliomaStatus unknownNCT04674579
• Pilot Study of Elemene in Treating Patients With Refractory GlioblastomaStatus unknownNCT04674527Phase 2
• TTFields and Radiosurgery of Recurrent Glioblastoma +/- 18F-Fluoro-Ethyl-ThyrosineActive, not recruitingNCT04671459Phase 2
• Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or MedulloblastomaActive, not recruitingNCT04661384Phase 1
• Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma PatientsCompletedNCT04657315Phase 1/2
• Longitudinal Assessment of Marrow and Blood in Patients With GlioblastomaSuspendedNCT04657146
• AB154 Combined With AB122 for Recurrent GlioblastomaActive, not recruitingNCT04656535Early Phase 1
• Study of CD200 Activation Receptor Ligand (CD200AR-L) and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent GlioblastomaStatus unknownNCT04642937Phase 1
• Early Integration of Palliative Care Using the BEACON PROQOL in Patients With High Grade Glioma and Their CaregiversCompletedNCT04630379Not applicable
• A Phase II, Open Label Study of ONC201 in Adults With EGFR-low GlioblastomaWithdrawnNCT04629209Phase 2
• Study of Pamiparib in Newly Diagnosed and rGBMCompletedNCT04614909Early Phase 1
• Innovative SonoCloud-9 Device for Blood Brain Barrier Opening in First Line Temozolomide Glioblastoma Patients.Status unknownNCT04614493Phase 2
• Safety of IMRT Treatment With Inhomogeneous Dose in Patients With Relapsed High-grade Gliomas.CompletedNCT04610229Not applicable
• Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a Surgical ResectionTerminatedNCT04608812Phase 1
• Surgical Nivolumab And Ipilimumab For Recurrent GBMActive, not recruitingNCT04606316Phase 1
• Evaluating the Effect of a Mobile Audio Companion (Elly) to Reduce Anxiety in Cancer PatientsCompletedNCT04604158Not applicable
• A Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients With Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT)Active, not recruitingNCT04600817Phase 2
• EAP for the Treatment of Glioblastoma With PVSRIPONo longer availableNCT04599647
• MR-guided LITT Therapy in Patients With Primary Irresectable GlioblastomaCompletedNCT04596930Not applicable
• 18F-PSMA PET/CT for Visualization of Glioblastoma MultiformeStatus unknownNCT04588454Not applicable
• ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma MultiformeActive, not recruitingNCT04587830Phase 2
• Neoadjuvant PD-1 in Newly Diagnosed GlioblastomaStatus unknownNCT04583020Phase 2
• Multiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed GlioblastomaActive, not recruitingNCT04574856Phase 2
• Evaluation of the Predictive Value of 18F-fluorodeoxyglucose Positron Emission Tomography and Brain Perfusion Computed Tomography for the Efficacy of Anti-angiogenic Therapy (Bevacizumab) in Recurrent GlioblastomaCompletedNCT04566185Not applicable
• Phase I Trial of DNA-PK Inhibitor (PEPOSERTIB ) in Combination With Radiation and Adjuvant Temozolomide in Newly Diagnosed MGMT Unmethylated and Recurrent GlioblastomaActive, not recruitingNCT04555577Phase 1
• A Trail of Fluzoparil in Combination With Temozolomide in Patients With Recurrent GlioblastomaStatus unknownNCT04552977Phase 2
• Dendritic Cell Vaccination With Standard Postoperative Chemoradiation for the Treatment of Adult GlioblastomaCompletedNCT04552886Phase 1
• Anlotinib Combined With Dose-dense Temozolomide for the First Recurrent or Progressive Glioblastoma After STUPP RegimenStatus unknownNCT04547855Phase 2
• Improving Understanding of Brain Tumors Through Preservation of Biologically Active Brain TissueActive, not recruitingNCT04545177Not applicable
• Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid TumorsTerminatedNCT04541225Phase 1
• Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent GlioblastomaActive, not recruitingNCT04528680Phase 1/2
• Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 MutationsActive, not recruitingNCT04521686Phase 1
• Precoce Medical Care by the Mobil Support for Patients With GlioblastomaCompletedNCT04516733Not applicable
• Open-Label Pilot Study of OPTUNE® With High Density Transducer Arrays for the Treatment of Recurrent GBMCompletedNCT04492163Phase 2
• Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBMTerminatedNCT04489420Phase 1
• Potentiation of Chemotherapy in Brain Tumors by ZincStatus unknownNCT04488783Not applicable
• A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With GlioblastomaActive, not recruitingNCT04485949Phase 2
• HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade GliomaWithdrawnNCT04482933Phase 2
• A Phase 1-2 Study of ST101 in Patients With Advanced Solid TumorsActive, not recruitingNCT04478279Phase 1/2

← Glioblastoma overview